Integrating IT After a Biotech Acquisition: The First 100 Days

Why the First 100 Days Need Their Own Plan

Deal activity explains why this topic matters now. BioWorld counted $186.69 billion in biopharma deal value through the first seven months of 2026, a 13 percent increase over the same period of 2025, which had been the previous record for that stretch.¹ PwC’s U.S. midyear deals outlook, as reported by Fierce Pharma, found that pharma and life sciences deal value passed $65 billion in the first quarter alone, the strongest quarter since 2020, with 16 M&A transactions of at least $1 billion each.² Each of those deals produces an integration, and each integration has a first 100 days.

Most of the integration writing in our industry addresses two other windows. Before close, the work is diligence: finding the unvalidated spreadsheet, the cloud contract with a punishing exit clause, the two engineers who hold the data platform in their heads. After the first quarter, the work is rationalization: deciding which of two LIMS survives and how to retire the other. The window between those two is different in kind. During the first 100 days, the buyer owns the company but does not yet own most of its regulatory relationships, many of its contracts, or the legal identity attached to its electronic records. The job is to keep everything working and compliant while those ownership facts change on their own schedules.

Ownership Changes Do Not Move Responsibilities Automatically

ICH Q10, the harmonized guideline on pharmaceutical quality systems, has a short section written for this situation. Section 2.8, Management of Change in Product Ownership, says that when product ownership changes, for example through an acquisition, management should “consider the complexity of this” and make sure that ongoing responsibilities are defined for each company involved and that “The necessary information is transferred.”³ Q10 also lists changes in product ownership among the external factors that management review should monitor.³

Those two sentences carry a lot of weight for IT. “Ongoing responsibilities” includes who owns each validated system, who approves changes to it, who performs access reviews, and who answers for its audit trail during an inspection. “Necessary information” includes validation packages, configuration records, user access histories, vendor qualification files, and the electronic records themselves. None of that moves because a share purchase agreement was signed. It moves because someone planned the move, documented it, and confirmed it happened.

Why Biotech Targets Make This Harder

A small or mid-size biotech target usually has three traits that shape the first 100 days. First, its IT estate is mostly SaaS: a cloud eQMS, a cloud document management system, an electronic data capture platform run by a CRO, a LIMS hosted by the vendor, and a Microsoft 365 or Google Workspace tenant that holds most of the unstructured records. Each of those is a contract with a named legal entity, and many are validated for GxP use under the target’s quality system.

Second, the target often depends heavily on outside parties. Contract manufacturers, contract testing labs, CROs, central labs, and specialty vendors hold large parts of its GxP record set. The quality agreements with those parties name the target as the owner or sponsor, and they define who keeps which records and how they are made available for inspection.

Third, the target’s people are few and specialized. The same three people may run IT, own system administration for the eQMS, and sign as business owner for the validation of the clinical data warehouse. Retention packages help, but some of those people will leave, and the first 100 days are when the knowledge they carry has to be written down.

Taken together, these traits mean the integration team cannot treat the target’s systems as ordinary corporate IT to be folded into the parent. They are regulated systems held under contracts and filings that name another company, operated by a handful of people whose departure would be felt immediately.

The Entity-of-Record Map: Build It Before Close

The most useful document an integration team can have on day one is not a network diagram or an application inventory. Both of those matter, and the diligence work should already have produced them. The document that drives first-100-day decisions is a map of legal ownership: for each thing the target holds, which legal entity is the owner of record today, which entity will be the owner of record after integration, and what event moves it.

Stock Purchase or Asset Purchase Changes Everything

The deal structure determines most of the map. In a stock purchase, the target company usually survives as a legal entity and becomes a subsidiary. Its INDs, its trial sponsorships, its establishment registrations, and its contracts stay with the same legal entity on the day of close. Nothing has to transfer on day one, which gives the integration team breathing room. The pressure comes later, when the buyer decides to merge the subsidiary into another entity or move products to a different holder, and every one of those records then needs a formal transfer.

In an asset purchase, or when the target is merged into the buyer at close, the picture is reversed. Applications, sponsorships, and contracts may need to move to a different legal entity quickly, and some of those moves require regulator action before they take effect. The integration team then has to run system changes in step with filings it does not control.

FDA’s own procedures reflect this difference. A CDER Office of Generic Drugs procedure on transfers of ownership, MAPP 5242.1, distinguishes a transfer of ownership under 21 CFR 314.72 from changes resulting from corporate mergers and acquisitions, which it defines as transfers between related entities under the same parent company. For that second category, the office does not treat the change as a transfer of ownership; the applicant instead requests a corporate name change, address change, or contact change with Form FDA 356h and a cover letter that gives the date of the merger or acquisition.⁵ That procedure governs generic drug applications, but the distinction it draws is the one every integration team should make explicit for its own portfolio: is the legal holder changing, or only its name and contacts?

What the Map Should Contain

The map does not need to be elaborate. A spreadsheet with one row per item and a small set of columns is enough, provided it is complete and owned by someone. The table below shows the layers that matter most for IT.

The last row deserves a short explanation. Part 11 requires persons using electronic signatures to certify to FDA that those signatures are intended to be the legally binding equivalent of handwritten signatures.¹³ In a stock purchase where the target entity survives, its existing certification usually continues to describe the entity using the signatures. Where records will be signed under a different legal entity after integration, regulatory affairs should confirm whether that entity has its own certification on file. This is a small task that is easy to forget because it does not live in any IT system.

Who Owns the Map

The map crosses legal, regulatory affairs, quality, and IT, which means it often belongs to nobody. Assign it to a named person in the integration management office, with named contributors from each function. Legal knows which contracts assign on change of control. Regulatory affairs knows which filings name which entity. Quality knows which agreements and systems are inside the quality system. IT knows which tenants, accounts, and subscriptions exist. None of them alone can produce the map, and a version produced by one function will be wrong in ways the others would have caught.

Day 1: Access, Email, and a Frozen Validated Estate

Day one has two goals that pull in different directions. The combined company needs to communicate and collaborate from the first morning. The target’s validated systems need to keep running exactly as they were validated. The way to meet both goals is to add access around the target’s environment without changing anything inside it.

Collaboration Without Tenant Changes

Many acquirers and biotech targets run on Microsoft 365, and the integration team’s first impulse is often to plan the tenant migration. That is a later decision. On day one, the goal is to let people find each other, meet, share files, and reach a small set of shared applications without moving any mailbox or account.

Microsoft’s own documentation lists mergers and acquisitions among the main reasons an organization ends up with more than one Microsoft Entra tenant.¹⁴ Its guidance on cross-tenant topologies describes an application hub pattern for exactly this case: cross-tenant synchronization provisions users from the acquired company into the parent’s tenant from day one, so they can reach shared applications such as the help desk or benefits system, while the larger IT decisions are still being made.¹⁵ Cross-tenant synchronization creates, updates, and deletes B2B collaboration users across tenants in the same organization, using the cross-tenant access settings that each tenant controls.¹⁴

This pattern has an important property for a regulated target: the target’s own tenant, its user accounts, and the identities that sign records in its validated systems do not change. The target’s users get a second, synchronized identity in the parent’s tenant for collaboration, while their primary identity, the one tied to their electronic signatures, stays where it was.

Email and the Fraud Window

The days around an announcement and close are a period of many legitimate changes to payment and contact details. Vendors receive notices about new billing entities. Employees receive messages about payroll, benefits, and new systems from unfamiliar senders. Finance teams process changes to remittance details. That is the environment business email compromise is built for.

The FBI’s Internet Crime Complaint Center describes business email compromise as a scam that targets businesses and individuals who perform legitimate transfer-of-funds requests, often by compromising real email accounts through social engineering or intrusion. Its 2024 public service announcement reported 305,033 domestic and international incidents and more than $55 billion in exposed losses between October 2013 and December 2023, with a 9 percent increase in identified global exposed losses between December 2022 and December 2023.¹⁷ The announcement does not break out acquisition-related cases, so we cannot say how many involved deals. The pattern, though, matches the conditions of an integration closely enough that day-one planning should treat it as a known risk.

Two technical steps support those controls. First, confirm that both companies’ domains publish sender authentication records. NIST’s Trustworthy Email guidance recommends Sender Policy Framework (SPF), DomainKeys Identified Mail (DKIM), and Domain-based Message Authentication, Reporting and Conformance (DMARC) as the mechanisms for authenticating a sending domain.¹⁸ If the buyer plans to send integration messages from a new domain or a third-party platform, that sender needs to be authenticated before day one, not after users start reporting the messages as phishing. Second, decide whether target users will see a banner on mail from the parent company’s domain. External sender banners are useful, but on day one they will flag every message from the new owner. Many teams add the parent’s domains to an allow list for the banner while keeping all other external checks in place.

Freeze the Validated Estate

On day one, every GxP system the target runs should be placed under an explicit integration freeze. That does not mean the systems stop. It means no configuration change, no authentication change, no hosting change, and no account restructuring happens to them except through the target’s existing change control process, with a documented reason that cites the integration.

The freeze protects something specific: the link between the validated configuration and the evidence that it was validated. A validated eQMS that suddenly authenticates through a different identity provider is not the system that was validated, even if every screen looks the same. The same is true for a LIMS whose service accounts are renamed to match the parent’s naming standard, or a document management system whose administrator role is handed to a parent-company IT group that has never been trained on it.

What Users Should Notice on Day One

From the point of view of a target employee, day one should feel like this: a welcome message from a known address, the ability to find and message new colleagues, perhaps access to one or two parent-company applications, and no change at all to the systems they use to do regulated work. If a QC analyst cannot log into the LIMS on day one because an integration step changed something, the integration has already created a deviation.

By Day 30: Identity, Security, and the Validated State

The first month is when the integration team builds an accurate picture of who can access what, closes the obvious security gaps, and confirms that every validated system has an owner who will answer for it. It is also when the first departures happen, and access must follow them.

Inherited Access Is the Main Security Exposure

AWS’s Mergers and Acquisitions Lens puts the security problem directly: “Mergers and acquisitions integrations significantly expand attack surface and risks.”¹⁶ The lens recommends assessing the security posture of the target, including privileged access, monitoring, and data protection; assessing the risks from new network connections between the companies and putting controls such as firewall rules and vulnerability scanning around them; monitoring closely for unauthorized access, credential leaks, and violations of least privilege; and training employees, with phishing simulations, during the transition.¹⁶

For a biotech target, inherited access usually includes some combination of the following: former employees and contractors whose SaaS accounts were never disabled, shared administrator accounts on lab instruments and their controlling PCs, vendor support accounts with standing remote access, API keys and service principals created by people who have left, and external sharing links on document libraries that were opened for a partner years ago. None of these are integration problems in themselves. They become integration problems when the buyer connects its network or tenant to the target’s environment and inherits whatever those accounts can reach.

Do Not Connect Networks Until You Know What Is on Them

The pressure to connect networks early is real. Shared file servers, shared applications, and shared printers are the most visible signs of a combined company. In a regulated target, the network often also carries lab instruments running older operating systems, manufacturing or warehouse systems, and controlling PCs that cannot be patched without revalidation. A flat connection between the buyer’s corporate network and that environment exposes systems that were never designed for it.

For the first 30 days, prefer application-level access, such as cross-tenant synchronization, published applications, and specific firewall rules for named services, over network-level interconnection. When a network connection is required, scope it to named systems, document it as a change under the target’s quality system if it touches GxP infrastructure, and put monitoring on it from the first day.

Access Control Under Part 11 and Annex 11

Two regulatory requirements shape how identity work is done in the first month. Part 11 requires that each electronic signature be unique to one individual and “shall not be reused by, or reassigned to, anyone else,” and it requires controls that keep each combination of identification code and password unique and that periodically check, recall, or revise those credentials.¹³ EU GMP Annex 11 requires that the creation, change, and cancellation of access authorizations be recorded, and that the extent of security controls match the criticality of the computerized system.¹²

These requirements rule out some common integration shortcuts. Renaming a departed scientist’s account so a new hire can inherit their mailbox and system roles is a reassignment of an identity that has signed GxP records. Bulk-renaming user IDs to match the parent’s naming convention breaks the link between historical audit trail entries and the person who made them, unless the system preserves the old identifier and the change is documented. Removing a whole group of target accounts on a fixed date, because the parent’s identity system will take over, can strand records that still need review or approval by those users.

The safe pattern is to treat every identity change in a GxP system as a change to that system, assessed and recorded under change control, with a documented link between old and new identifiers where the system supports it.

Departures and Knowledge Capture

Retention plans rarely keep everyone, and in a small biotech a single departure can remove the only person who knows how a system is configured. The first 30 days are the time to capture what those people know. For each GxP system, confirm that the current validation package, configuration specification, and administrator procedures exist and match the system as it runs today. Where they do not, have the person who knows the system write it down while they are still employed. This is not new validation work. It is making the existing state legible to the people who will own it next.

Offboarding during integration also needs extra care. A departing system administrator’s accounts must be disabled promptly, but their responsibilities must be reassigned before that happens, with the reassignment recorded. A system whose only administrator has been disabled is a system that nobody can maintain, which is its own compliance problem.

Validated State: What Counts as a Change

A change in corporate ownership is not, by itself, a change to a computerized system. The validated state of the target’s eQMS does not lapse because the shares changed hands. But many things done because of the ownership change are changes, and they should be assessed as such. Annex 11 requires that changes to a computerized system, including its configuration, be made only in a controlled manner under a defined procedure, and that systems be periodically evaluated to confirm they remain in a valid state.¹²

One more Annex 11 provision becomes important here. Annex 11 says that when third parties are used to provide, configure, integrate, validate, maintain, or modify a computerized system, formal agreements must exist that clearly state the third party’s responsibilities, and it adds that “IT-departments should be considered analogous.”¹² When the parent company’s IT organization starts supporting the target’s GxP systems, it is taking on a role that, under Annex 11, needs defined responsibilities. A short internal service description, approved by the target’s quality unit, is the practical answer.

By Day 100: Quality Agreements and Vendor Contracts That Name the Old Entity

By the end of the first quarter, the integration team should know every quality agreement and every GxP-relevant vendor contract the target holds, who it names, whether it survives the deal unchanged, and what has to be amended. This is less visible work than tenant migration, but it is what inspectors will look at if something goes wrong at a contract site.

Why Quality Agreements Matter to IT

FDA’s guidance on quality agreements for contract manufacturing describes how owners and contract facilities should define, establish, and document their manufacturing activities, and it identifies quality and change control as the most critical pieces of a quality agreement. It recommends that quality agreements be separate from, or at least severable from, commercial contracts such as master services or supply agreements, and it notes that “Quality agreements may be reviewed during inspections.”¹⁰ The guidance also says a quality agreement should define each party’s role in making and keeping original records or true copies, explain how records will be made readily available for inspection, and indicate that electronic records will be stored under CGMP and be immediately retrievable for the required retention period.¹⁰

EU GMP Chapter 7 takes the same position for outsourced activities: “There must be a written Contract between the Contract Giver and the Contract Acceptor which clearly establishes the duties of each party.”¹¹ Chapter 7 also places ultimate responsibility for controlling outsourced activities with the contract giver’s quality system.¹¹

For IT, the records clauses are the ones that matter. They define where a CDMO’s batch records, a contract lab’s raw data, and a CRO’s trial data are kept, in what systems, and how the owner gets access. When the owner changes, or when the owner’s systems change, those clauses can stop describing reality. A quality agreement that says the contract lab will upload results to “the Sponsor’s LIMS” means something specific. If the integration plan retires that LIMS in month eight, the agreement needs to change first.

Three Kinds of Contract Exposure

A Practical Triage

Start with a single list of every agreement that touches GxP work: quality agreements with CDMOs, contract labs, CROs, central labs, packagers, and distributors; SaaS contracts for validated systems; and service contracts for hosting, backup, and IT support of GxP infrastructure. For each item, record the named parties, the term, the assignment and change-of-control terms, the records and systems clauses, and the date of the last supplier audit.

Then sort the list by what the integration plan will do to it. Agreements whose systems and parties will not change in the next year need only a contact update. Agreements whose legal party will change, because an entity is being merged or a product is being transferred, need an amendment or a new agreement timed to the legal change. Agreements whose records clauses name a system the integration plan will retire need to be amended before the system changes, and the amendment should be part of the change control for the system retirement.

SaaS Vendors Hosting Validated Systems

SaaS contracts for GxP systems need specific attention because the vendor’s role under Annex 11 is defined by the formal agreement between the regulated company and the vendor.¹² When the licensee entity changes, confirm with the vendor that the move is an administrative change to the account and not a migration to a new instance. Some vendors handle a change of licensee by re-papering the existing tenant. Others create a new tenant and migrate data, which is a data migration under Annex 11 and needs to be validated as one. Ask before signing the assignment, and get the answer in writing.

Also confirm that the vendor’s quality agreement, if there is a separate one, moves with the subscription, and that the vendor knows who the new quality contacts are. A vendor that sends its change notifications for a validated SaaS release to an email address belonging to someone who left in month one is a vendor whose releases are no longer being assessed.

By Day 100: Data Transfer and Record Ownership

The buyer acquired the target in large part for its data: preclinical results, CMC data, clinical data, and the regulatory record that supports its filings. The first 100 days are the time to establish who owns that data as a matter of record, where the authoritative copies are, and what can and cannot be moved.

Ownership Is Not the Same as Location

After close, the buyer owns the target’s data in a commercial sense, but the regulatory record is still tied to the entity that created it and to the systems and agreements under which it was created. An audit trail in the target’s eQMS records actions by target employees under the target’s procedures. Those records do not need to be relabeled to show the new owner, and they should not be. Their value as evidence depends on staying exactly as they were created.

Where a marketing application does move to a new owner, the regulations expect the new owner to have the full record. Under 21 CFR 314.72, the new owner of an application must submit either a statement that it has “a complete copy of the approved application, including supplements and records that are required to be kept under § 314.81,” or a request for a copy from FDA’s files.⁴ That is a records requirement, and IT is usually the function that has to prove it can be met.

Migration Rules Apply From the First Copy

Annex 11 says that when data are transferred to another data format or system, validation should include checks that data “are not altered in value and/or meaning during this migration process.”¹² It also says archived data should be checked for accessibility, readability, and integrity, and that if relevant changes are made to the system, the ability to retrieve the data should be ensured and tested.¹²

These rules apply to more integration activity than teams expect. Copying a SharePoint library of signed batch record PDFs into the parent’s tenant is a data transfer. Exporting a LIMS database so the parent’s data team can load it into an analytics platform creates a copy that is not the record, and it needs to be labeled as such. Moving files from the target’s file server to a cloud repository so the server can be shut down is a migration of whatever GxP records are on that server.

In the first 100 days, the rule we recommend is simple: copies may be made for business use, but authoritative GxP records stay in their validated systems of origin, and any copy outside those systems is marked as a non-authoritative copy. The planned migrations come later, under the rationalization program, with migration validation done properly.

Clinical Data and the Trial Master File

Clinical data is often the most valuable and the most dispersed. It may sit in a CRO’s EDC system, a central lab’s portal, an IRT vendor’s platform, and the target’s own eTMF, all under agreements that name the target as sponsor. Until the sponsor of record changes, those systems should continue to operate under the target’s name and its user role assignments.

When the sponsor of record does change, the timing matters. EMA’s description of the CTIS change-of-sponsor process states that the change takes effect only after all member states concerned authorize the substantial modification, and that roles under the initial sponsor become obsolete at that point, so sponsor users need to manage role assignments for the new sponsor before authorization.⁸ The same principle is worth applying to the CRO and vendor systems: plan the user role changes before the sponsor change takes effect, so there is no gap in who can access and act on trial data.

Personal Data in the Transfer

Clinical data, employee data, and pharmacovigilance data contain personal data, and moving them between legal entities or across borders raises privacy obligations that are separate from GxP. Privacy counsel should review any transfer of personal data between entities before it happens, including transfers that seem administrative, such as consolidating HR records into the parent’s system. This is one more reason to avoid bulk data moves in the first 100 days. The legal basis for each transfer needs to be settled first.

Regulatory Filings and System Ownership Changes

Regulatory filings set the timetable for many system ownership changes. IT cannot move a product’s safety database, labeling system, or submission gateway account to a new entity before the filing that changes the holder of record, and it cannot leave them in place for long afterward. The integration plan should treat each filing as a dependency with a date.

United States: Applications, INDs, and Registrations

For approved drug applications, 21 CFR 314.72 lets an applicant transfer ownership of its application. The former owner submits a letter stating that all rights have been transferred. The new owner submits a signed application form and a letter that commits to the agreements, promises, and conditions made by the former owner, gives the effective date of the change, and addresses whether it has a complete copy of the application.⁴ The new owner must also advise FDA of changes in the conditions of the approved application under 314.70, with an exception that allows changes to the product’s brand or the manufacturer, packer, or distributor name on labeling to be reported in the next annual report.⁴

For investigational applications, FDA’s IND reporting page says that all IND amendments and reports should include Form FDA 1571, and that Form FDA 1572 should be included if the amendment concerns a change in application sponsor or the addition of a new investigator.⁶ In practice, a sponsor change involves correspondence from both the former and new sponsor, and regulatory affairs will own the details. IT’s role is to make sure the new sponsor can submit electronically on the effective date, and that the former sponsor’s gateway accounts and authorization letters are handled in an orderly way rather than disabled in the middle of an open submission.

For establishments, 21 CFR 207.29 requires registrants to update registration information within 30 calendar days after closing or selling an establishment, changing an establishment’s name or physical address, or changing the name, mailing address, telephone number, or email address of the official contact or U.S. agent.⁹ Contact changes are the trap here. If the target’s official contact leaves in month one, the 30-day clock for updating that contact starts at the change, not at the end of the integration.

European Union: Marketing Authorizations and Clinical Trials

EMA’s questions and answers on transfers of marketing authorization define a transfer as the procedure that moves a marketing authorization from the current holder to a new holder that is a different person or legal entity. A change of name or address of the holder is not a transfer if the holder remains the same legal entity; that is notified as a variation instead.⁷ The same distinction between a surviving entity and a new one appears again, and the entity-of-record map should show which case applies to each authorization.

Where a transfer does occur, EMA asks for a document stating the implementation date on which the transferor and transferee finalize the transitional arrangements and the transferee takes over all responsibilities. The period between the Commission decision and the implementation date should be proportionate to the work involved and should not exceed six months.⁷ The application also includes an updated summary of the pharmacovigilance system master file under the transferee’s name, including proof that the transferee has a qualified person responsible for pharmacovigilance.⁷ EMA directs marketing authorization holders to use its IRIS platform when managing transfers after the original submission.⁷

That six-month window is an IT planning input. Safety case processing, signal management, and literature monitoring systems may need to change hands, or at least change the legal entity under which they operate, within that window. The transition plan should state which entity’s systems process safety cases on each day of the transitional period, so that no case is missed or processed twice.

For EU clinical trials under the Clinical Trials Regulation, the July 2024 CTIS release introduced a dedicated Part I substantial modification type for change of sponsor, used to move a trial to a different sponsor.⁸ As described above, the definite change happens only after authorization by all member states concerned, and user roles under the original sponsor become obsolete at that point.⁸ Sponsor administrators for the new sponsor should be set up and assigned in advance.

Turning Filings Into an IT Calendar

This table is not a substitute for regulatory advice on any specific product, and regulatory affairs owns every one of these filings. What it shows is that each filing has an IT dependency with a date, and that those dates should be in the integration plan rather than discovered when a submission fails.

What Not to Change in the First 100 Days

Integration programs are measured on progress, and progress usually means visible change. In a regulated biotech, much of the most valuable work in the first 100 days is deciding what will stay the same, writing that down, and defending it. The list below is what we would ask an integration steering committee to agree to before close.

The Do-Not-Change List

• Authentication for validated systems. Keep GxP systems on the identity provider they were validated with. Plan the cutover as a validated change after day 100.
• Primary user identities. Do not rename, merge, or reassign user IDs that have signed GxP records. Part 11 does not allow an electronic signature to be reused by or reassigned to anyone else.¹³
• Tenant ownership and email domains for the target. Use cross-tenant collaboration for day-one needs. Tenant consolidation is a rationalization decision, not a day-one task.
• Authoritative record locations. Copies for business use are fine if labeled. Authoritative records stay in their validated systems until a validated migration moves them.
• Quality agreement records clauses. Do not change the systems named in a quality agreement before the agreement is amended.
• The target’s quality procedures for its systems. Harmonizing SOPs is important work, but swapping procedures under running systems without a transition plan creates gaps in what was followed and when.
• Backup, disaster recovery, and business continuity arrangements. Annex 11 expects documented and tested continuity arrangements for systems that support critical processes.¹² Keep the tested arrangement in place until the replacement is tested.
• Regulatory gateway and portal accounts. Do not disable or reassign submission and safety reporting accounts until the filing that changes the holder of record is effective and the new accounts are working.
• Vendor-hosted GxP instances. Do not request tenant moves, instance merges, or configuration standardization from SaaS vendors in the first 100 days.

What Is Safe to Change

Plenty can and should change in the first 100 days. Collaboration access, a shared intranet, new HR and benefits systems for non-GxP processes, security monitoring, endpoint protection on standard office devices, phishing training, access reviews, removal of orphaned accounts through normal procedures, and contact updates in contracts and registrations are all appropriate early work. The difference between this list and the do-not-change list is not importance. It is whether the change touches the evidence that a regulated system works as validated and that its records are attributable and complete.

The Day-100 Checkpoint

At day 100, the integration team should be able to show the steering committee a short set of facts. The entity-of-record map is complete and approved by legal, regulatory affairs, quality, and IT. Every GxP system has a named owner, administrator, and quality contact. A user access review has been completed on each validated system. Every GxP-relevant agreement has been triaged, with amendments scheduled. A records register exists. Every pending filing has an IT dependency and a date in the plan. No validated system has had an unassessed change.

With those facts in place, the program can move into application portfolio rationalization, tenant consolidation, and harmonization of procedures. Those decisions are easier and faster when the first 100 days have produced an accurate record of who owns what, rather than a combined company that looks integrated on the surface but whose regulatory relationships, contracts, and records were never reconciled underneath.

Conclusion

The first 100 days after a biotech acquisition are not the time to make the target look like the parent. They are the time to make sure that every regulated relationship the target holds keeps working while ownership changes on its own legal and regulatory schedule. ICH Q10’s guidance on changes in product ownership comes down to two obligations: define who is responsible for what, and make sure the necessary information moves. For IT, that means an entity-of-record map, a frozen validated estate, disciplined identity work, a triage of every agreement that names the old entity, a records register, and a calendar of filings that drive system changes. None of it is glamorous, and all of it is what an inspector or a regulator would ask to see if something goes wrong in the first year.

Sakara Digital works with pharma and biotech organizations on the regulated side of integration: validated systems, quality agreements, records, and the IT decisions that depend on them. If you are planning the first 100 days of an acquisition and want an independent perspective on what to change, what to protect, and in what order, we are happy to have that conversation.

For Further Reading